Wed.May 29, 2024

article thumbnail

With ruling, Pfizer can escape some claims in legal battle over Chantix carcinogen allegations

Fierce Pharma

Pfizer chalked up a key win in its legal battle surrounding the now-recalled smoking cessation drug Chantix after a New York judge narrowed the scope of the arguments in play. | The company still faces some claims in a class action lawsuit over the now-recalled smoking cessation med Chantix.

275
275
article thumbnail

How to Get Into Medical Device Sales: Ultimate Career Guide

David Bagga

How to Get Into Medical Device Sales: Ultimate Career Guide Home Blog How to Get Into Medical Device Sales: Ultimate Career Guide How to Get Into Medical Device Sales: Ultimate Career Guide If you are new to medical device sales and interested in getting a job in this field, here are some essential tips that […] The post How to Get Into Medical Device Sales: Ultimate Career Guide appeared first on.

Sales 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After 5-year quest to streamline cell and gene therapy production, Ori Biotech reveals automated platform

Fierce Pharma

After half a decade spent developing an automated manufacturing platform, Ori Biotech believes it's ready to make a mark on the cell and gene therapy field. | Ori has revealed an automated cell and gene therapy manufacturing platform. The company says its tech is flexible enough to transition between projects at various stages of development.

article thumbnail

How to Get Medical Device Sales Jobs with No Experience?

David Bagga

How to Get Medical Device Sales Jobs with No Experience? Home Blog How to Get Medical Device Sales Jobs with No Experience? How to Get Medical Device Sales Jobs with No Experience? Medical device sales become one of the best career options today. More and more people want to crack medical device sales jobs and […] The post How to Get Medical Device Sales Jobs with No Experience?

Sales 130
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Neurocrine, a regular name on Wall Street’s M&A lists, elevates BD chief to succeed founder and CEO

Fierce Pharma

Neurocrine Biosciences’ dealmaking prospects may soon get another round of attention with the installment of a new CEO. | Neurocrine Biosciences' dealmaking prospects may get another round of attention with the installment of a new CEO. The neuroscience company's three-decade veteran Kevin Gorman will soon hand the top job to long-time BD chief Kyle Gano.

article thumbnail

How to Become A Medical Device Sales Rep in 2024?

David Bagga

Medical device sales is a burgeoning market, with jobs that have an extremely high earning potential. In 2018, the average base salary of a medical sales representative was $92,698 How to Become A Medical Device Sales Rep in 2024? Home Blog How to Become A Medical Device Sales Rep in 2024? How to Become A […] The post How to Become A Medical Device Sales Rep in 2024?

Sales 130

More Trending

article thumbnail

How to Become A Medical Sales Rep With No Experience 2024?

David Bagga

Medical device sales is a burgeoning market, with jobs that have an extremely high earning potential. In 2018, the average base salary of a medical sales representative was $92,698 How to Become A Medical Sales Rep With No Experience 2024? Home Blog How to Become A Medical Sales Rep With No Experience 2024? How to […] The post How to Become A Medical Sales Rep With No Experience 2024?

article thumbnail

Tris Pharma captures FDA nod for non-stimulant ADHD treatment Onyda XR

Fierce Pharma

Stimulants are typically the go-to option for doctors prescribing treatments for attention-deficit hyperactivity disorder (ADHD). | Tris Pharma has won FDA approval for Onyda XR (clonidine hydrochloride). The extended-release oral suspension becomes the first liquid non-stimulant medication for ADHD and the only non-stimulant with nighttime dosing in the indication.

Pharma 200
article thumbnail

How Much Do Medical Device Sales Reps Make in 2024?

David Bagga

How Much Do Medical Device Sales Reps Make in 2024? Home Blog How Much Do Medical Device Sales Reps Make in 2024? How Much Do Medical Device Sales Reps Make in 2024? When looking for a medical device sales rep job, a common question is, ‘How much does a medical device sales rep earn? It’s […] The post How Much Do Medical Device Sales Reps Make in 2024?

Sales 130
article thumbnail

Amgen grabs FDA thumbs up for Soliris biosim, eyes 2025 launch

Fierce Pharma

Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its planned Stelara biosim rollout in 2025. | Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its planned Stelara biosim rollout in 2025. But thanks to a new FDA approval, the company is nearing yet another biosimilar launch.

FDA 158
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

J.D. Power: Customer Experience Gap Grows Among Commercial Health Plans

MedCity News

A new J.D. Power ranking of commercial health plans found a major difference in customer satisfaction between the top and bottom-ranked health plans. The post J.D. Power: Customer Experience Gap Grows Among Commercial Health Plans appeared first on MedCity News.

119
119
article thumbnail

Can robots break the cell therapy bottleneck?

PharmaVoice

A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

article thumbnail

A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Fierce Pharma

Already weathering the complex biopharma landscape in the U.S.

Biopharma 130
article thumbnail

Digital therapeutics firm Akili agrees $34 million takeover

pharmaphorum

More consolidation in the digital health sector as Akili agrees a $34m takeover by Virtual Therapeutics, returning to private hands.

119
119
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Two novel biosimilars approved in EU and US

European Pharmaceutical Review

The European Commission (EC) has granted the first approval for an omalizumab biosimilar in Europe. Omlyclo ® (CT-P39) is authorised as a biosimilar referencing Xolair ®. CT-P39 is indicated for allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP). The authorisation is based on clinical data, including findings from a Phase III clinical trial comparing Omlyclo ® to the reference product in patients with chronic spontaneous urticaria up to

article thumbnail

Inside the Tech El Camino Health Is Using to Fight the Nurse Burnout Crisis

MedCity News

Deb Muro, CIO of El Camino Health, explained some of the ways her health system is using technology to make nurses’ jobs easier — including software that flags patients who are at risk of adverse outcomes and a tool that helps frontline nurse managers better engage with their staff. The post Inside the Tech El Camino Health Is Using to Fight the Nurse Burnout Crisis appeared first on MedCity News.

article thumbnail

LBP-immunotherapy could benefit oncology patients

European Pharmaceutical Review

The safety and tolerability of rationally-designed live bacterial product (LBP) BMC128 combined with nivolumab has shown initial positive trends in non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC), new data from an ongoing Phase I clinical trial suggests. Biomica’s microbiome -based immuno-oncology candidate and the anti-PD1 immune checkpoint inhibitor is being evaluated in eleven participants.

article thumbnail

Working for a mature form of genomic medicines

pharmaphorum

In a new episode of the pharmaphorum podcast, Rahul Kakkar, CEO of gene editing company Tome, speaks with web editor Nicole Raleigh about programmable genomic integration (PGI) technology.

Medicine 118
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

FDA Enforcement Discretion: A Strategic Path to Market for Digital Health and Digital Therapeutics Companies

Nixon Gwilt Law

Healthcare delivery is changing, and digital health is revolutionizing healthcare, creating a burgeoning market opportunity for software-as-a-medical-device (SaMD) and digital therapeutic (DTx) products. These innovations can improve patient outcomes while creating revenue potential through direct-to-consumer sales, contracts with health plans, and existing billing codes like the remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) code sets.

article thumbnail

Why Prevention-Focused Strategies Are Key

MedCity News

Five ways stakeholders can promote screening and treatment for elevated Lp(a) in the future to improve overall cardiac disease mortality The post Why Prevention-Focused Strategies Are Key appeared first on MedCity News.

99
article thumbnail

AstraZeneca throws its hat into the oral PCSK9 ring

pharmaphorum

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol.

111
111
article thumbnail

Roche’s PI3K inhibitor wins FDA priority review for breast cancer

Pharmaceutical Technology

The US FDA has set an action date of 27 November for the combination therapy of Roche’s inavolisib, Pfizer’s Ibrance, and fulvestrant.

FDA 96
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Update: MSD confirms $3bn takeover of EyeBio

pharmaphorum

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular degeneration (AMD).

114
114
article thumbnail

MedCity FemFwd: How Employers Can Improve Maternal Health Outcomes

MedCity News

In this episode, we’re joined by Randa Deaton, vice president of purchaser engagement at the Purchaser Business Group on Health. She talks about the organization’s new Comprehensive Maternity Care Common Purchasing Agreement. The post MedCity FemFwd: How Employers Can Improve Maternal Health Outcomes appeared first on MedCity News.

article thumbnail

Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024

Pharmaceutical Technology

Ensifentrine is a first-in-class dual phosphodiesterase 3/4 inhibitor to treat chronic obstructive pulmonary disease (COPD).

98
article thumbnail

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

pharmaphorum

Amgen’s Bkemv is first FDA-approved biosimilar to AstraZeneca’s Soliris in the US, getting interchangeable status for rare diseases PNH and aHUS

FDA 105
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA approves Amgen’s interchangeable biosimilar Bkemv

Pharmaceutical Technology

The US FDA has approved Amgen's Bkemv as an interchangeable biosimilar to Soliris for the treatment of specific rare diseases.

FDA 95
article thumbnail

BHF awards £35m funding to nine UK universities for cardiovascular disease

PharmaTimes

Affecting more than 7 million people in the UK, cardiovascular diseases are conditions that affect the heart or circulation

82
article thumbnail

BMS stakes $80m on Prothena’s neurodegenerative candidate

Pharmaceutical Technology

Prothena plans to initiate a Phase I trial in an undisclosed indication by the end of 2024.

105
105
article thumbnail

Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition

MedCity News

Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug. The post Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition appeared first on MedCity News.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A